Gratepanche Sylvie, Gamain Benoit, Smith Joseph D, Robinson Bridget A, Saul Allan, Miller Louis H
Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Rockville, MD 20852, USA.
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13007-12. doi: 10.1073/pnas.2235588100. Epub 2003 Oct 20.
The variant antigen Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), present on the surface of P. falciparum-parasitized erythrocytes (PE), plays a central role in naturally acquired immunity, although antibodies to PfEMP1 are predominantly variant specific. To overcome this major limitation for vaccine development, we immunized mice with three cysteine-rich interdomain 1 (CIDR1) domains of PfEMP1 that have the critical function of binding the PE to CD36 on endothelium and thus preventing spleen-dependent killing of the parasite. The immunizations consisted of different combinations of three CIDR1 encoded by DNA followed by recombinant protein boost. Immunizations with a single variant in a prime-boost regimen induced no or low cross-reactivity toward heterologous CIDR1; however, a broad range of crossreactivity was detected in mice that were immunized with all three variants simultaneously. The induced crossreactivity suggests that an anti-PfEMP1 vaccine may be possible.
恶性疟原虫红细胞膜蛋白1(PfEMP1)变异抗原存在于恶性疟原虫寄生的红细胞(PE)表面,在自然获得性免疫中起核心作用,尽管针对PfEMP1的抗体主要是变异特异性的。为克服疫苗研发的这一主要限制,我们用PfEMP1的三个富含半胱氨酸的结构域间区域1(CIDR1)免疫小鼠,这些结构域具有将PE与内皮细胞上的CD36结合的关键功能,从而防止寄生虫被脾脏依赖的杀伤。免疫接种由DNA编码的三个CIDR1的不同组合,随后用重组蛋白加强。在初免-加强方案中用单一变异体免疫未诱导出对异源CIDR1的交叉反应或仅有低交叉反应;然而,在同时用所有三个变异体免疫的小鼠中检测到广泛的交叉反应。诱导的交叉反应表明抗PfEMP1疫苗可能是可行的。